Position in ACLX
as of Mar 31, 2026
· filed May 14, 2026
Position Value
$17,498,568
New position
Shares Held
152,400
first reported quarter
Ownership
0.261%
of shares outstanding
% of Portfolio
2.81%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2026
1 quarter on record
Voting authority
Sole 100%
Shared 0%
None 0%
Position in Biotechnology
Healthcare · as of Mar 31, 2026GABELLI & Co INVESTMENT ADVISERS, INC. holds $57,586,363 across 10 Biotechnology names. ACLX ranks #1 (30.4% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ACLX |
Arcellx, Inc.
This page
|
152,400 | $17,498,568 | |
| 2 | FOLD |
AMICUS THERAPEUTICS, INC.
|
777,340 | $11,240,336 | |
| 3 | TERN |
Terns Pharmaceuticals, Inc.
|
205,700 | $10,844,504 | |
| 4 | APLS |
Apellis Pharmaceuticals, Inc.
|
200,600 | $8,070,138 | |
| 5 | DAWN |
Day One Biopharmaceuticals, Inc.
|
325,350 | $6,975,504 | |
| 6 | RVMD |
Revolution Medicines, Inc.
|
13,400 | $1,303,150 | |
| 7 | CYTK |
Cytokinetics Inc
|
13,578 | $894,925 | |
| 8 | CNTA |
Centessa Pharmaceuticals plc
|
9,400 | $373,368 |
All Filings in ACLX
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $17,498,568 | 152,400 | Shares | Sole | 2026-05-14 | |
| No filing history on record for this holder in this stock. | ||||||